SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

04 Feb 2026 Evaluate
The Revenue for the quarter ended  December 2025 of Rs. 4005.10 millions grew by 7.38 % from Rs. 3729.80 millions.The Net Loss for the quarter ended December 2025 is Rs. -200.00 millions as compared to Net Loss of Rs. -102.30 millions of corresponding quarter ended December 2024Operating Profit saw a handsome growth to 330.70 millions from 244.00 millions in the quarter ended December 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 4005.10 3729.80 7.38 12351.60 11709.40 5.48 15181.90 17908.10 -15.22
Other Income 71.70 42.60 68.31 192.90 119.80 61.02 184.80 85.10 117.16
PBIDT 330.70 244.00 35.53 1134.10 1365.60 -16.95 1465.20 2664.90 -45.02
Interest 201.50 140.00 43.93 657.70 406.50 61.80 566.30 368.20 53.80
PBDT 69.10 113.90 -39.33 411.00 969.00 -57.59 908.80 2412.00 -62.32
Depreciation 273.60 247.50 10.55 801.90 733.70 9.30 982.50 879.80 11.67
PBT -204.50 -133.60 53.07 -390.90 235.30 -266.13 -73.70 1532.20 -104.81
TAX -4.50 -31.30 -85.62 -60.80 60.20 -201.00 13.60 365.80 -96.28
Deferred Tax -4.50 19.10 -123.56 -60.80 30.90 -296.76 13.60 38.10 -64.30
PAT -200.00 -102.30 95.50 -330.10 175.10 -288.52 -87.30 1166.40 -107.48
Equity 184.50 184.40 0.05 184.50 184.40 0.05 184.50 184.40 0.05
PBIDTM(%) 8.26 6.54 26.22 9.18 11.66 -21.27 9.65 14.88 -35.15

Indoco Remedies Share Price

212.30 0.00 (0.00%)
22-Apr-2026 12:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1661.70
Dr. Reddys Lab 1223.70
Cipla 1235.95
Zydus Lifesciences 929.60
Lupin 2316.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×